We are live on
!
Find out more
BCM
Bronte Capital Management Portfolio holdings
AUM
$1.01B
1-Year Est. Return
47.99%
This Fund
S&P 500
This Quarter
Est. Return
+11.82%
1 Year Est. Return
+47.99%
3 Year Est. Return
+112.22%
5 Year Est. Return
+138.3%
10 Year Est. Return
–
AUM
$1B
AUM Growth
-$114M
(-10%)
Cap. Flow
-$99.2M
Cap. Flow
% of AUM
-9.89%
Top 10 Holdings %
Top 10 Hldgs %
77.87%
Holding
47
New
17
Increased
3
Reduced
23
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BBB Foods
TBBB
|
+$11.8M |
| 2 |
Bath & Body Works
BBWI
|
+$3.09M |
| 3 |
Fair Isaac
FICO
|
+$2.7M |
| 4 |
Nice
NICE
|
+$2.45M |
| 5 |
Turning Point Brands
TPB
|
+$2.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$34M |
| 2 |
Capital One
COF
|
+$19.7M |
| 3 |
Interactive Brokers
IBKR
|
+$18.4M |
| 4 |
ABVX
Abivax
ABVX
|
+$14.9M |
| 5 |
iShares Core S&P Small-Cap ETF
IJR
|
+$12.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.65% |
| 2 | Healthcare | 15.18% |
| 3 | Communication Services | 14.31% |
| 4 | Consumer Staples | 9.74% |
| 5 | Consumer Discretionary | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Riskified
RSKD
$694M
| $2.55M | 0.25% |
513,676
-20
| -0% | -$96 |
|
|
27
Nice
NICE
$5.79B
| $2.3M | 0.23% |
+20,322
| New | +$2.45M |
|
28
Universal Display
OLED
$3.68B
| $1.36M | 0.14% |
+11,653
| New | +$1.51M |
|
29
James River Group Holdings
JRVR
$208M
| $786K | 0.08% |
+123,575
| New | +$711K |
|
30
Enovix
ENVX
$892M
| $84.4K | 0.01% |
11,550
| – | – |
|
31
Fractyl Health
GUTS
$109M
| $37.2K | ﹤0.01% |
+16,905
| New | +$27.2K |
|
32
Alector
ALEC
$168M
| $30.1K | ﹤0.01% |
+19,282
| New | +$34.2K |
|
33
Coherus Oncology
CHRS
$217M
| $27.4K | ﹤0.01% |
+19,282
| New | +$28.1K |
|
34
Invivyd
IVVD
$158M
| $27.2K | ﹤0.01% |
+11,012
| New | +$22.9K |
|
35
Caribou Biosciences
CRBU
$145M
| $24.8K | ﹤0.01% |
+15,627
| New | +$32.8K |
|
36
Pliant Therapeutics
PLRX
$64.4M
| $22.7K | ﹤0.01% |
+18,613
| New | +$28K |
|
37
Fate Therapeutics
FATE
$286M
| $22.5K | ﹤0.01% |
+22,853
| New | +$27.4K |
|
38
Milestone Pharmaceuticals
MIST
$138M
| $21K | ﹤0.01% |
+10,414
| New | +$22.4K |
|
39
Rani Therapeutics
RANI
$87M
| $20.1K | ﹤0.01% |
+14,868
| New | +$22.4K |
|
40
C4 Therapeutics
CCCC
$385M
| $19.2K | ﹤0.01% |
+10,033
| New | +$23.8K |
|
|
ABVX
41
Abivax
ABVX
$10.9B
| – | – |
-156,747
| Closed | -$14.9M |
|
|
42
iShares Core S&P Small-Cap ETF
IJR
$109B
| – | – |
-95,350
| Closed | -$12.7M |
|
43
CALL
iShares Russell 2000 Growth ETF
IWO
$14.3B
| – | – |
-18,700
| Closed | -$5.98M |
|
Similar funds
EPAM
AG
GA
CT
AH
PIM
WA
MIM
Bronte Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Bronte Capital Management held 47 positions worth $1B, down 10% from $1.12B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Bronte Capital Management withdrew a net $99.2M in Q4 2025, closing 3 positions and reducing 23 holdings. Its most notable exit was Abivax, an estimated $14.9M position sold in full.
By sector, the portfolio is most concentrated in Financials at 26% of assets, down from 30% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Bronte Capital Management opened a new position in BBB Foods worth $13.2M.
- Bronte Capital Management's largest Q4 2025 buy was BBB Foods: 394,158 shares worth $13.2M.
- Bronte Capital Management added most to Bath & Body Works in Q4 2025, an estimated $3.09M increase.
- Bronte Capital Management's biggest Q4 2025 reduction was iShares Biotechnology ETF, cutting an estimated $34M.
- Bronte Capital Management fully exited Abivax in Q4 2025, selling an estimated $14.9M.
- Bronte Capital Management's ten largest holdings make up 78% of its $1B portfolio in Q4 2025.
- Bronte Capital Management opened 17 new positions and closed 3 in Q4 2025.
- Bronte Capital Management's portfolio value fell 10% quarter-over-quarter to $1B.
Based on Bronte Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.